Please check your internet connection and try again.
# Sompraz HP
## Overview
Sompraz HP is a combination medication containing pantoprazole, amoxicillin, and clarithromycin, used for the eradication of *Helicobacter pylori* infection. Pantoprazole is a proton pump inhibitor (PPI), amoxicillin is a penicillin-class antibiotic, and clarithromycin is a macrolide antibiotic.
## Primary Indications
* Eradication of *Helicobacter pylori* in patients with peptic ulcer disease or a history of peptic ulcer disease.
## Adult Dosing
The typical adult dosage regimen is as follows:
* Pantoprazole 40 mg orally once daily.
* Amoxicillin 1000 mg orally twice daily.
* Clarithromycin 500 mg orally twice daily.
This regimen is generally prescribed for 7 to 14 days. The exact duration depends on local guidelines and clinician judgment.
## Pediatric Dosing
Pediatric dosing is not well-established and should be determined by a specialist based on the child's weight and clinical condition.
## Dose Adjustments
* **Renal Impairment:** No specific dose adjustment is typically recommended for pantoprazole, amoxicillin, or clarithromycin in mild to moderate renal impairment. However, caution and monitoring are advised. In severe renal impairment, caution and potential dose reduction may be considered, particularly for amoxicillin and clarithromycin, as per their individual prescribing information.
* **Hepatic Impairment:** Pantoprazole dose reduction may be considered in severe hepatic impairment. Dose adjustments for amoxicillin and clarithromycin are generally not required in hepatic impairment unless there is severe liver dysfunction.
## Contraindications
* Hypersensitivity to pantoprazole, amoxicillin, clarithromycin, or any component of the formulation.
* History of hypersensitivity to penicillins, cephalosporins, or other beta-lactam antibiotics.
* History of cholestatic jaundice or hepatic dysfunction associated with prior clarithromycin use.
* Use in patients with severe renal impairment or hepatic impairment requires careful consideration.
* Concomitant use with certain medications, such as cisapride, pimozide, and specific statins (e.g., lovastatin, simvastatin), due to potential for serious adverse events (e.g., QT prolongation, rhabdomyolysis).
## Adverse Effects
Common adverse effects include:
* **Gastrointestinal:** Diarrhea, nausea, abdominal pain, vomiting, taste perversion.
* **Other:** Headache, rash, dizziness, elevated liver enzymes.
* **Serious:** Allergic reactions (including anaphylaxis), *Clostridioides difficile*-associated diarrhea, QT prolongation, hepatic dysfunction, severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis).
## Key Drug Interactions
* **CYP3A4 Inhibitors/Substrates:** Clarithromycin is a moderate inhibitor of CYP3A4. Concomitant use with CYP3A4 substrates may increase serum concentrations of these drugs, potentially leading to toxicity (e.g., cisapride, pimozide, certain statins, benzodiazepines, anticoagulants).
* **Warfarin:** Potential for increased anticoagulant effect.
* **Proton Pump Inhibitors:** Pantoprazole can decrease gastric pH, potentially affecting the absorption of other drugs (e.g., ketoconazole, itraconazole, certain HIV medications).
* **Amoxicillin:** May decrease the efficacy of oral contraceptives.
* **Probenecid:** Can decrease the renal excretion of amoxicillin and pantoprazole.
## Monitoring
* Monitor for signs and symptoms of hypersensitivity reactions.
* Assess for effectiveness in *H. pylori* eradication (e.g., urea breath test, stool antigen test, or serologic testing, typically performed at least 4 weeks after treatment completion).
* Monitor for gastrointestinal side effects, particularly diarrhea, which could indicate *C. difficile* infection.
* Consider liver function tests in patients with pre-existing hepatic conditions or during prolonged therapy.
* Monitor for signs of QT prolongation, especially in patients with risk factors.
## Clinical Pearls
* This combination therapy is designed for a specific duration; patient adherence is crucial for successful eradication.
* Advise patients to take all prescribed medications as directed, even if they feel better.
* Inform patients about potential side effects and when to seek medical attention.
* Ensure patients are not allergic to penicillins or macrolides before prescribing.
* Consider local resistance patterns for clarithromycin when initiating therapy.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and local guidelines before making treatment decisions.*
